Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
non-Hodgkin lymphoma
Biotech
Genmab sheds another clinical ADC from $1.8B ProfoundBio buy
The Danish pharma dropped GEN1160 after poor enrollment in a phase 1/2 cancer trial.
Darren Incorvaia
Nov 17, 2025 2:17pm
Innate antibody pits NK cells against lymphoma in animal models
Nov 15, 2024 2:00pm
Merck pays $700M for bispecific challenger to Amgen cancer drug
Aug 9, 2024 8:52am
ASH: AZ spinout Dizal explores FDA path, US partner for PTCL med
Dec 11, 2023 4:30am
C4 culls phase 1/2 cancer program after efficacy fail
Nov 1, 2023 11:29am
Soligenix shares take another dip as FDA requests 2nd trial
Apr 14, 2023 11:02am
